The potential role of adherence factors in probiotic function in the gastrointestinal tract of adults and pediatrics: a narrative review of experimental and human studies. (31st December 2022)

• Record Type: Journal Article
• Authors: Gorreja, Frida; Walker, W. Allan
• Is Part Of: Gut microbes. Volume 14:Isuse 1(2022)
• Publication Date: 2022-12-31
• Subjects: Probiotic adhesion -- immune interaction -- IECs interaction -- surface structures of bacteria -- pathogen inhibition; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2022.2149214
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTRACT: Numerous studies point to the important role of probiotic bacteria in gastrointestinal health. Probiotics act through mechanisms affecting enteric pathogens, epithelial barrier function, immune signaling, and conditioning of indigenous microbiota. Once administered, probiotics reach the gastrointestinal tract and interact with the host through bacterial surface molecules, here called adhesion factors, which are either strain- or specie-specific. Probiotic adhesion, through structural adhesion factors, is a mechanism that facilitates persistence within the gastrointestinal tract and triggers the initial host responses. Thus, an understanding of specific probiotic adhesion mechanisms could predict how specific probiotic strains elicit benefits and the potential of adherence factors as a proxy to predict probiotic function. This review summarizes the present understanding of probiotic adherence in the gastrointestinal tract. It highlights the bacterial adhesion structure types, their molecular communication with the host and the consequent impact on intestinal diseases in both adult and pediatric populations. Finally, we discuss knockout/isolation studies as direct evidence for adhesion factors conferring anti-inflammatory and pathogen inhibition properties to a probiotic. What is known : Probiotics can be used to treat clinical conditions. Probiotics improve dysbiosis and symptoms. Clinical trials may not confirm in vitro and animal studies. What is new : Adhesion structures may be important for probiotic function. Need to systematically determine physical characteristics of probiotics before selecting for clinical trials. Probiotics may be genetically engineered to add to clinical efficacy.